Paul Weiss-Guided GSK To License Liver Drug For $690M
GlaxoSmithKline has agreed to license its experimental liver disease drug linerixibat to Italian pharmaceutical company Alfasigma, which focuses on serious liver conditions, for up to $690 million....To view the full article, register now.
Already a subscriber? Click here to view full article